Price Alert

IGM Biosciences Inc. (IGMS)

NASDAQ: IGMS · Real-Time Price · USD

1.27

0.00 (0.00%)

At close: Aug 13, 2025, 3:59 PM

0.00% (1D)

Bid	1.25
Market Cap	77.5M
Revenue (ttm)	145.05M
Net Income (ttm)	-53.38M
EPS (ttm)	-0.9
PE Ratio (ttm)	-1.4111111111111112
Forward PE	-0.91
Analyst	Hold

Ask	1.29
Volume	1,588,637
Avg. Volume (20D)	634,437
Open	1.27
Previous Close	1.27
Day's Range	1.27 - 1.27
52-Week Range	0.92 - 22.50
Beta	0.59

About IGMS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IGMS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IGMS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

IGM Biosciences has released their quartely earnings on Jul 31, 2025:

Revenue of $143.62M exceeds estimates by $142.1M, with 11353.19% YoY growth.

EPS of 1.58 exceeds estimates by 1.70, with 300.00% YoY growth.

Next Earnings Release

IGM Biosciences Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+15.18%

IGM Biosciences shares are trading higher after th... Unlock content with Pro Subscription

7 months ago

-66.29%

IGM Biosciences shares are trading lower after the company announced it is halting further development of Imvotamab and IGM-2644.

News

1 month ago · zacks.com

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of a loss of $0.3 per share. This compares to a loss of $0.79 per share a year ag...

2 months ago · businesswire.com

IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of IGM Biosciences, Inc. (NASDAQ: IGMS) to Concentra Biosciences, LLC is fair to IGM shareho...